VIPDOMET 12.5/500; 12.5 mg alogliptin (as benzoate) / 500 mg metformin hydrochloride film-coated tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

vipdomet 12.5/500; 12.5 mg alogliptin (as benzoate) / 500 mg metformin hydrochloride film-coated tablets blister pack

takeda pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 500 mg; alogliptin benzoate, quantity: 17 mg (equivalent: alogliptin, qty 12.5 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; mannitol; magnesium stearate; titanium dioxide; hypromellose; crospovidone; povidone; purified talc; iron oxide yellow - vipdomet is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,vipdomet can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

VIPDOMET 12.5/850; 12.5 mg alogliptin (as benzoate) / 850 mg metformin hydrochloride film-coated tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

vipdomet 12.5/850; 12.5 mg alogliptin (as benzoate) / 850 mg metformin hydrochloride film-coated tablets blister pack

takeda pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 850 mg; alogliptin benzoate, quantity: 17 mg (equivalent: alogliptin, qty 12.5 mg) - tablet, film coated - excipient ingredients: titanium dioxide; crospovidone; povidone; microcrystalline cellulose; mannitol; purified talc; magnesium stearate; iron oxide yellow; hypromellose - vipdomet is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,vipdomet can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

TRAJENTAMET 2.5 mg/1000 mg linagliptin 2.5 mg / metformin hydrochloride 1000 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

trajentamet 2.5 mg/1000 mg linagliptin 2.5 mg / metformin hydrochloride 1000 mg film-coated tablet blister pack

boehringer ingelheim pty ltd - metformin hydrochloride, quantity: 1000 mg; linagliptin, quantity: 2.5 mg - tablet, film coated - excipient ingredients: copovidone; propylene glycol; magnesium stearate; arginine; iron oxide red; hypromellose; colloidal anhydrous silica; titanium dioxide; maize starch; purified talc - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate, in patients inadequately controlled on metformin alone, or those already being treated and well controlled with the free combination of linagliptin and metformin. trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. trajentamet is indicated in combination with an sglt2 inhibitor (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor. trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

TRAJENTAMET 2.5 mg/1000 mg linagliptin 2.5 mg / metformin hydrochloride 1000 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

trajentamet 2.5 mg/1000 mg linagliptin 2.5 mg / metformin hydrochloride 1000 mg film-coated tablet bottle

boehringer ingelheim pty ltd - metformin hydrochloride, quantity: 1000 mg; linagliptin, quantity: 2.5 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; propylene glycol; maize starch; purified talc; hypromellose; iron oxide red; arginine; magnesium stearate; titanium dioxide; copovidone - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate, in patients inadequately controlled on metformin alone, or those already being treated and well controlled with the free combination of linagliptin and metformin. trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. trajentamet is indicated in combination with an sglt2 inhibitor (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor. trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

Melkart Duo 50mg/850mg film-coated tablets Malta - English - Medicines Authority

melkart duo 50mg/850mg film-coated tablets

g.l. pharma gmbh schlossplatz 1, 8502 lannach, austria - vildagliptin, metformin hydrochloride - film-coated tablet - vildagliptin 50 mg metformin hydrochloride 850 mg - drugs used in diabetes

Melkart Duo 50mg/1000mg film-coated tablets Malta - English - Medicines Authority

melkart duo 50mg/1000mg film-coated tablets

g.l. pharma gmbh schlossplatz 1, 8502 lannach, austria - vildagliptin, metformin hydrochloride - film-coated tablet - vildagliptin 50 mg metformin hydrochloride 1000 mg - drugs used in diabetes

Sitagliptin/Metformin hydrochloride Krka 50 mg/1000 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

sitagliptin/metformin hydrochloride krka 50 mg/1000 mg film-coated tablets

krka, d.d., novo mesto - sitagliptin; metformin hydrochloride - film-coated tablet - 50 mg/1000 milligram(s) - metformin and sitagliptin

Sitagliptin/Metformin hydrochloride Krka 50 mg/850 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

sitagliptin/metformin hydrochloride krka 50 mg/850 mg film-coated tablets

krka, d.d., novo mesto - sitagliptin; metformin hydrochloride - film-coated tablet - 50 mg/850 milligram(s) - metformin and sitagliptin

Sitagliptin/Metformin hydrochloride Rowex 50/1000 mg Film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

sitagliptin/metformin hydrochloride rowex 50/1000 mg film-coated tablets

rowex ltd - sitagliptin hydrochloride; metformin hydrochloride - film-coated tablet - 50/1000 milligram(s) - metformin and sitagliptin

Sitagliptin/Metformin hydrochloride Rowex 50/850 mg Film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

sitagliptin/metformin hydrochloride rowex 50/850 mg film-coated tablets

rowex ltd - sitagliptin hydrochloride; metformin hydrochloride - film-coated tablet - 50/850 milligram(s) - metformin and sitagliptin